[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Pascual-Castroviejo I, Pascual-Pascual SI, Rafia S, Viaño J: [Hemangiomas, and cutaneous and intracranial vascular deformations (Pascual-Castroviejo syndrome tipe II ). A case report]. Rev Neurol; 2002 Dec 1-15;35(11):1034-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemangiomas, and cutaneous and intracranial vascular deformations (Pascual-Castroviejo syndrome tipe II ). A case report].
  • [Transliterated title] Hemangiomas y malformaciones vasculares cutáneas e intracraneales (sindrome de Pascual-Castroviejo tipo II). Presentacion de un caso.
  • OBJECTIVE: To present a case with several cutaneous hemangiomas associated with intracranial hemangiomas and possibly with an intrahepatic hemangioma.
  • CASE REPORT: A boy, 17 months old, showing several cutaneous hemangiomas and epileptic seizures resisting to antiepileptic medication, who also presented psychomotor retardation.
  • The study by angiographic magnetic resonance (AMR ) revealed the presence of three small intracranial angiomas and possibly a hepatic hemangioma.
  • The seizures were controlled with antiepileptic medication.
  • CONCLUSION: This case shows the association of the cutaneous hemangiomas and the subjacent vascular alterations also hemangiomas in this patient which are included in the most frequent neurocutaneous disease, which is known as Pascual Castroviejo syndrome.
  • [MeSH-major] Brain Neoplasms / pathology. Hemangioma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Anticonvulsants / therapeutic use. Humans. Infant. Liver Neoplasms / pathology. Magnetic Resonance Angiography. Male. Psychomotor Disorders. Seizures / drug therapy. Syndrome


2. Ontachi Y, Asakura H, Omote M, Yoshida T, Matsui O, Nakao S: Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid. Haematologica; 2005 Nov;90 Suppl:ECR29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid.
  • A 39-year-old woman with an enlarging giant liver hemangioma was diagnosed as having KMS with DIC.
  • To control the hemorrhagic diathesis, we commenced combination therapy for DIC with danaparoid (1,250 Ux2/day, intravenously (IV)) and tranexamic acid (0.5 g x 3/day, peros (PO).
  • Rapid improvement of the bleeding tendency and coagulopathy occurred in response to this treatment - that is, DIC was controlled without removing the giant hemangioma.
  • The therapy did not restrict the behavior of the patient by continuous drip and angiography could be performed without bleeding.
  • Such therapy may be beneficial in chronic DIC with activation of fibrinolysis.
  • [MeSH-major] Antifibrinolytic Agents / therapeutic use. Chondroitin Sulfates / therapeutic use. Dermatan Sulfate / therapeutic use. Disseminated Intravascular Coagulation / etiology. Hemangioma / complications. Hemorrhagic Disorders / etiology. Heparitin Sulfate / therapeutic use. Liver Neoplasms / complications. Tranexamic Acid / therapeutic use
  • [MeSH-minor] Adult. Blood Proteins / analysis. Drug Therapy, Combination. Female. Hepatic Artery / surgery. Humans. Ligation. Syndrome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266920.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antifibrinolytic Agents; 0 / Blood Proteins; 24967-94-0 / Dermatan Sulfate; 6T84R30KC1 / Tranexamic Acid; 83513-48-8 / danaproid; 9007-28-7 / Chondroitin Sulfates; 9050-30-0 / Heparitin Sulfate
  •  go-up   go-down


3. Schiavetti A, De Pasquale MD, Di Salvo S, Ventriglia F, Clerico A: Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report. Pediatr Hematol Oncol; 2003 Mar;20(2):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report.
  • Four cutaneous angiomas were noted.
  • Instrumental examinations revealed congestive heart failure and multiple focal lesions in the liver with typical features of hemangiomas.
  • The therapy with subcutaneous interferon-alfa-2a (IFN-alpha) was administered for 12 months with progressive regression of cutaneous hemangiomas, liver lesions, and cardiological alterations.
  • IFN-alpha therapy was effective without any significant adverse effects.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Heart Failure / etiology. Hemangioma / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / congenital. Abdominal Neoplasms / drug therapy. Digitalis Glycosides / therapeutic use. Diuretics / therapeutic use. Dyspnea / etiology. Female. Furosemide / therapeutic use. Head and Neck Neoplasms / congenital. Head and Neck Neoplasms / drug therapy. Heart Septal Defects, Atrial / complications. Heel. Hemangioma, Capillary / congenital. Hemangioma, Capillary / drug therapy. Hemangioma, Cavernous / congenital. Hemangioma, Cavernous / drug therapy. Hepatomegaly / etiology. Humans. Infant. Knee. Neoplasms, Multiple Primary / congenital. Neoplasms, Multiple Primary / drug therapy. Recombinant Proteins. Remission Induction

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12554528.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Digitalis Glycosides; 0 / Diuretics; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


Advertisement
4. Mason KP, Koka BV, Eldredge EA, Fishman SJ, Burrows PE: Perioperative considerations in a hypothyroid infant with hepatic haemangioma. Paediatr Anaesth; 2001 Mar;11(2):228-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative considerations in a hypothyroid infant with hepatic haemangioma.
  • Hepatic haemangiomas in infants are rare.
  • An infant with both a hepatic haemangioma and a severe hypothyroid condition, unresponsive to conventional thyroxine therapy, will be described.
  • This case presented here is the perioperative management of a critically ill infant who had myocardial depression secondary to hypothyroidism and a hepatic haemangioma that required embolization.
  • To our knowledge, this is the first published report describing intravenous triiodothyronine as a therapeutic modality to stabilize a hypothyroid infant prior to undergoing a general anaesthetic.
  • [MeSH-major] Congenital Hypothyroidism. Hemangioma / surgery. Liver Neoplasms / surgery. Preoperative Care
  • [MeSH-minor] Anesthesia, General. Decompression, Surgical. Embolization, Therapeutic. Humans. Hypothyroidism / complications. Hypothyroidism / drug therapy. Infant. Infusions, Intravenous. Laparotomy. Male. Triiodothyronine / administration & dosage

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11240884.001).
  • [ISSN] 1155-5645
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 06LU7C9H1V / Triiodothyronine
  •  go-up   go-down


5. Bessho K, Etani Y, Ichimori H, Miyoshi Y, Namba N, Yoneda A, Ooue T, Chihara T, Morii E, Aoki T, Murakami M, Mushiake S, Ozono K: Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism. Eur J Pediatr; 2010 Feb;169(2):215-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism.
  • INTRODUCTION: Infantile hepatic hemangioma with consumptive hypothyroidism is a rare condition.
  • CASE REPORT: A 4-month-old girl presented with diffuse hepatic hemangiomas during treatment of congenital hypothyroidism.
  • Serum reverse triiodothyronine was elevated, and her hypothyroidism improved concomitant with involution of the hemangioma following prednisolone and interferon-alpha administration.
  • At 20 months of age, 7 months after discontinuing prednisolone and interferon-alpha, a focal hemangioma regrew from one of the previous lesions and was surgically resected.
  • The expression and activity of type 3 iodothyronine deiodinase (D3) were elevated in the resected tumor tissue compared with placenta.
  • DISCUSSION: Here, we describe a patient with consumptive hypothyroidism and diffuse infantile hepatic hemangiomas, one of which regrew after involution following pharmacotherapy.
  • CONCLUSION: It is important to identify infantile hepatic hemangioma in patients with hypothyroidism refractory to hormone replacement therapy, who have low free triiodothyronine despite high thyrotropin and normal free thyroxine levels, and long-term follow-up will be needed for these patients.
  • [MeSH-major] Hemangioma / enzymology. Hypothyroidism / complications. Iodide Peroxidase / metabolism. Liver Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Infant. Liver / metabolism. Liver / pathology. Magnetic Resonance Imaging. Polymerase Chain Reaction. RNA, Neoplasm / genetics. Time Factors

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Int. 2008 Aug;28(7):1043-4 [18783545.001]
  • [Cites] Paediatr Anaesth. 2001 Mar;11(2):228-32 [11240884.001]
  • [Cites] J Pediatr Endocrinol Metab. 2008 Jul;21(7):701-3 [18780606.001]
  • [Cites] Arch Dermatol. 2001 May;137(5):559-70 [11346333.001]
  • [Cites] Pediatrics. 1970 Jan;45(1):71-6 [5410252.001]
  • [Cites] J Pediatr Surg. 2007 Jan;42(1):62-7; discussion 67-8 [17208542.001]
  • [Cites] J Pediatr. 2001 Jun;138(6):932-5 [11391345.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):1021-4 [16544297.001]
  • [Cites] Pediatrics. 2003 Dec;112(6 Pt 1):1424-6 [14654623.001]
  • [Cites] Pediatrics. 2000 Jan;105(1 Pt 1):117-20 [10617714.001]
  • [Cites] J Perinatol. 2001 Dec;21(8):568-70 [11774023.001]
  • [Cites] Horm Res. 2005;63(2):86-9 [15711094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19097-102 [16365311.001]
  • [Cites] Eur J Pediatr. 1996 May;155(5):423-4 [8741047.001]
  • [Cites] J Pediatr Surg. 2006 Oct;41(10):1783-5 [17011291.001]
  • [Cites] J Pediatr Surg. 1978 Apr;13(2):155-62 [77324.001]
  • [Cites] J Pediatr Surg. 1996 Nov;31(11):1563-7 [8943124.001]
  • [Cites] Mol Cell Endocrinol. 1999 Jan 25;147(1-2):49-56 [10195691.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):200-9 [14991538.001]
  • [Cites] J Pediatr Surg. 1999 Jan;34(1):98-105; discussion 105-6 [10022152.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):185-9 [10900278.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Nov;22(11):1705 [17914938.001]
  • [Cites] Pediatr Pathol. 1988;8(6):625-31 [2469076.001]
  • [Cites] Pediatr Radiol. 1983;13(5):297-300 [6622093.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1997 Mar;24(3):348-51 [9138183.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):785-95 [14975986.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3117-28 [15240580.001]
  • [Cites] Curr Opin Pediatr. 2008 Apr;20(2):213-5 [18332720.001]
  • [Cites] Pediatr Hematol Oncol. 2006 Dec;23 (8):639-47 [17065140.001]
  • (PMID = 19548001.001).
  • [ISSN] 1432-1076
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm; EC 1.11.1.- / iodothyronine deiodinase type III; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


6. Farruggia P, Alaggio R, Cardella F, Tropia S, Trizzino A, Ferrara F, D'Angelo P: Focal nodular hyperplasia of the liver: an unusual association with diabetes mellitus in a child and review of literature. Ital J Pediatr; 2010;36:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal nodular hyperplasia of the liver: an unusual association with diabetes mellitus in a child and review of literature.
  • Hepatic hemangioma, adenoma and focal nodular hyperplasia are the most frequent benign lesions of the liver, but they are all infrequent among pediatric population.
  • The reports of focal nodular hyperplasia in children have recently increased in number, with many cases associated to drug intake, particularly to chemotherapy.
  • [MeSH-major] Diabetes Mellitus, Type 1 / complications. Focal Nodular Hyperplasia / complications
  • [MeSH-minor] Biopsy. Child. Diagnosis, Differential. Follow-Up Studies. Hepatectomy / methods. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1441-54 [10584697.001]
  • [Cites] J Hepatol. 2008 Jul;49(1):61-71 [18466996.001]
  • [Cites] Am J Gastroenterol. 2002 Sep;97(9):2371-3 [12358258.001]
  • [Cites] J Hepatol. 2008 Jan;48(1):163-70 [17997499.001]
  • [Cites] Hepatology. 2006 Jul;44(1):7-14 [16799965.001]
  • [Cites] Pediatr Radiol. 2005 Dec;35(12):1234-9 [16052333.001]
  • [Cites] Arch Pathol Lab Med. 1999 Sep;123(9):846-9 [10458838.001]
  • [Cites] HPB Surg. 1992 Apr;5(3):171-6; discussion 176-80 [1324705.001]
  • [Cites] J Surg Oncol. 1986 Oct;33(2):129-35 [3762186.001]
  • [Cites] Gastroenterol Jpn. 1984 Oct;19(5):419-23 [6083895.001]
  • [Cites] Zentralbl Allg Pathol. 1983;127(1-2):135-43 [6858421.001]
  • [Cites] Am J Med. 1976 Dec;61(6):871-7 [188336.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1975 Nov;83(6):615-22 [171910.001]
  • [Cites] J Hepatol. 2004 Apr;40(4):660-8 [15030983.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):651-9 [12612904.001]
  • [Cites] Gut. 2002 Jun;50(6):877-80 [12010893.001]
  • (PMID = 20504362.001).
  • [ISSN] 1824-7288
  • [Journal-full-title] Italian journal of pediatrics
  • [ISO-abbreviation] Ital J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2883986
  •  go-up   go-down


7. Nord KM, Kandel J, Lefkowitch JH, Lobritto SJ, Morel KD, North PE, Garzon MC: Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature. Pediatrics; 2006 Sep;118(3):e907-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature.
  • Multiple cutaneous hemangiomas can be associated with internal hemangiomas, with the liver being the most common site.
  • Here we report a case of a premature female neonate who presented with cardiac failure at birth and had typical-appearing infantile hemangiomas on the skin in association with vascular lesions in the liver.
  • Her clinical presentation was felt to be consistent with cutaneous and hepatic infantile hemangiomas.
  • After failure to respond to systemic steroids and chemotherapy, she underwent liver transplantation.
  • Histopathologic evaluation of the liver revealed a diagnosis of type 2 infantile hepatic hemangioendothelioma (regarded as synonymous with angiosarcoma) rather than benign infantile hemangioma of the liver.
  • Subsequent skin biopsies confirmed that her multiple cutaneous lesions were infantile hemangiomas and not metastatic angiosarcoma.
  • We report this case and a review of the literature on pediatric angiosarcoma of the liver associated with cutaneous infantile hemangiomas.
  • [MeSH-major] Hemangioma / pathology. Hemangiosarcoma / pathology. Liver Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Female. Heart Defects, Congenital. Humans. Infant, Newborn. Liver Transplantation

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatrics. 2007 Jun;119(6):1271
  • (PMID = 16880251.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


8. Takahashi A, Ogawa C, Kanazawa T, Watanabe H, Suzuki M, Suzuki N, Tsuchida Y, Morikawa A, Kuwano H: Remission induced by interferon alfa in a patient with massive osteolysis and extension of lymph-hemangiomatosis: a severe case of Gorham-Stout syndrome. J Pediatr Surg; 2005 Mar;40(3):E47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of massive osteolysis with lymphangioma and/or hemangioma (Gorham-Stout syndrome) has been controversial.
  • The authors report on a patient with multiple massive osteolyses and extensive lymph-hemangiomatosis whose lesions were reduced by interferon alfa therapy.
  • There were also hemangiomas in the liver and spleen, a tumor lesion in the left lower chest wall, and hemangiomatous change on the skin surface of the left back.
  • After steroid pulse therapy, pericardial effusion disappeared.
  • During these treatments, the 7th to 10th ribs disappeared from the x-ray and scoliosis developed.
  • One month later, a cloudy fluid collection in the right lung was found on computed tomography.
  • Interferon alfa and steroid pulse therapy were started.
  • Steroids were also reduced and maintained at 5 mg/d of predonine.
  • Ten months later, hemangioma in the back disappeared, and the 7th to 10th ribs, which had disappeared, reappeared.
  • The interferon alfa therapy was stopped 14 months after it was administered.
  • At this time, computed tomography shows regression of the hemangiomatous lesion in the back.
  • Interferon alfa with or without steroid therapy should be a choice for patients with extension lesions.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Interferon-alpha / therapeutic use. Osteolysis, Essential / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Antineoplastic Agents / therapeutic use. Child, Preschool. Chylothorax / etiology. Drug Therapy, Combination. Female. Femur / pathology. Hemangioma / drug therapy. Humans. Liver Neoplasms / drug therapy. Lymphangioma / complications. Lymphangioma / drug therapy. Neoplasms, Multiple Primary / drug therapy. Picibanil / therapeutic use. Pleural Effusion / etiology. Pulmonary Atelectasis / etiology. Remission Induction. Ribs / pathology. Scoliosis / etiology. Skin Neoplasms / drug therapy. Spine / pathology. Splenic Neoplasms / drug therapy. Syndrome. Thoracic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793714.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 39325-01-4 / Picibanil
  •  go-up   go-down


9. Chan KL, Tang MH, Tse HY, Tang RY, Lam HS, Lee CP, Tam PK: Factors affecting outcomes of prenatally-diagnosed tumours. Prenat Diagn; 2002 May;22(5):437-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Medical records of all fetuses referred to our institutions with antenatally-diagnosed tumours were reviewed for the type and location of the tumours, results of treatment and/or causes of death.
  • RESULTS: From January 1994 to May 2001, there were 15 fetuses with antenatally- diagnosed tumours: mesoblastic nephroma (MN) (n=2); neuroblastoma (NB) (n=2); cystic hygroma (CH) (n=3); intracranial germ cell tumour (IGCT) (n=2); sacrococcygeal teratoma (SCT) (n=3) and haemangioma (liver, n=2; limb, n=1).
  • One baby had cardiac failure resulting from a lower limb haemangioma and needed drug therapy.
  • All solid tumours (MN, NB, SCT) of the live births had no recurrence after surgery with or without adjuvant chemotherapy.
  • Solid tumours are relatively benign.
  • [MeSH-minor] Adult. Female. Gestational Age. Humans. Pregnancy. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 12001204.001).
  • [ISSN] 0197-3851
  • [Journal-full-title] Prenatal diagnosis
  • [ISO-abbreviation] Prenat. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Isaacs H Jr: Fetal and neonatal hepatic tumors. J Pediatr Surg; 2007 Nov;42(11):1797-803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal and neonatal hepatic tumors.
  • BACKGROUND/PURPOSE: Although hepatic tumors are uncommon in the perinatal period they are associated with significant morbidity and mortality in affected patients.
  • The purpose of this review is to focus on the fetus and neonate in an attempt to determine the various ways liver tumors differ clinically and pathologically from those found in the older child and adult and to show that certain types of tumors have a better prognosis than others.
  • METHODS: The author conducted a retrospective review of perinatal hepatic tumors reported in the literature and of patients treated and followed up at Children's Hospital San Diego and Children's Hospital Los Angeles.
  • Discussion of the differential diagnosis and pathologic findings of hepatic tumors in the fetus and neonate are described elsewhere and will not be discussed here in detail (Perspect Pediatr Pathol 1978;4:217; Weinberg AG, Finegold MJ.
  • Primary hepatic tumors in childhood.
  • Liver tumors. In: Isaacs H Jr, editor.
  • Liver tumors. In: Isaacs H Jr, editor.
  • RESULTS: One hundred ninety-four fetuses and neonates presented with hepatic tumors diagnosed prenatally (n = 56) and in the neonatal period (n = 138).
  • The study consisted of 3 main tumors: hemangioma (117 cases, 60.3%), mesenchymal hamartoma (45 cases, 23.2%), and hepatoblastoma (32 cases, 16.5%).
  • Half of the fetuses and neonates with hepatoblastoma had abnormally elevated serum alpha-fetoprotein levels compared with 16 (14%) of 117 of those with hemangioma and 1 neonate with mesenchymal hamartoma.
  • There were 76 (65%) examples of solitary (unifocal) hemangiomas and 41 (35%) of multifocal (which included the entity diffuse hemangiomatosis) with 86% and 71% survival rates, respectively.
  • There was some relationship between histologic type and prognosis.
  • Fifteen of 32 hepatoblastoma patients received surgical resection with or without chemotherapy, resulting in 7 (47%) of 15 cures.
  • The 56 fetuses and 138 neonates with hepatic tumors (hemangioma, mesenchymal hamartoma, and hepatoblastoma) had survival rates of 75%, 64%, and 25%, respectively.
  • CONCLUSIONS: The study shows that clinical findings in fetuses and neonates with hepatic tumors are less well defined than in older children.
  • Some hepatic tumors have a better prognosis than others.
  • Neonates with focal (solitary) hepatic hemangiomas have the best outcome and fetuses with hepatoblastoma the worst.
  • Although infantile hemangioma undergoes spontaneous regression, it may be life threatening when congestive heart failure and/or consumptive coagulopathy occur.
  • Mesenchymal hamartoma is a benign lesion best treated by surgical resection, which usually results in cure.
  • Pre- or postoperative chemotherapy is reserved for those patients with unresectable tumors or metastatic disease.
  • Because of the danger of labor-induced rupture of the tumor and potentially fatal intraabdominal hemorrhage, cesarean delivery is recommended when a hepatic tumor is found on prenatal ultrasound.
  • [MeSH-major] Hamartoma / congenital. Hemangioma / congenital. Hepatoblastoma / congenital. Liver Neoplasms / congenital. Liver Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022426.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


11. Sampol Bas C, Peña Viloria C: [Uptake of 123I-MIBG in a hepatic hemangioma in the scintigraphic study of an adrenal gland lesion]. Rev Esp Med Nucl; 2005 May-Jun;24(3):191-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uptake of 123I-MIBG in a hepatic hemangioma in the scintigraphic study of an adrenal gland lesion].
  • [Transliterated title] Captación de 123I-MIBG en un hemangioma hepático en el estudio gammagráfico de una lesión suprarrenal.
  • MRI confirmed the presence of a mass in the left adrenal gland suggestive of an adenoma and found a lesion in the right hepatic area at the level of the previously seen MIBG image.
  • This lesion was labelled as a hemangioma and would explain the findings of the isotopic study with MIBG.
  • The increased catecholamine serum and urine levels were due to drug interactions.
  • [MeSH-major] 3-Iodobenzylguanidine. Adrenal Glands / radiography. Diagnostic Errors. Hemangioma / radionuclide imaging. Iodine Radioisotopes. Liver Neoplasms / radionuclide imaging
  • [MeSH-minor] Adenoma / diagnosis. Adrenal Gland Neoplasms / diagnosis. Adrenergic Uptake Inhibitors / adverse effects. Adrenergic Uptake Inhibitors / pharmacology. Adrenergic Uptake Inhibitors / therapeutic use. Antidepressive Agents / adverse effects. Antidepressive Agents / pharmacology. Antidepressive Agents / therapeutic use. Antipsychotic Agents / adverse effects. Antipsychotic Agents / pharmacology. Antipsychotic Agents / therapeutic use. Catecholamines / blood. Diagnosis, Differential. Drug Interactions. False Positive Reactions. Female. Fibula / injuries. Fibula / radiography. Fractures, Bone / complications. Fractures, Bone / radiography. Humans. Incidental Findings. Magnetic Resonance Imaging. Middle Aged. Pheochromocytoma / diagnosis. Psychotic Disorders / complications. Psychotic Disorders / drug therapy. Tibial Fractures / complications. Tibial Fractures / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847786.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Adrenergic Uptake Inhibitors; 0 / Antidepressive Agents; 0 / Antipsychotic Agents; 0 / Catecholamines; 0 / Iodine Radioisotopes; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


12. Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N: Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. Pediatr Dermatol; 2010 Mar-Apr;27(2):195-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol.
  • A 27-day-old male infant with diffuse hemangiomatosis of the skin and liver was treated with oral propranolol at a dosage of 2 mg/kg per day.
  • Five months later skin and liver hemangiomas regressed almost completely.
  • Although the risk appears small, increased vigilance for hypoglycemia in children on chronic propranolol treatment who have decreased caloric intake for any reason seems prudent.
  • [MeSH-major] Hemangioma / drug therapy. Hypoglycemia / chemically induced. Liver Neoplasms / drug therapy. Propranolol / adverse effects. Propranolol / therapeutic use
  • [MeSH-minor] Energy Intake. Humans. Infant, Newborn. Ketone Bodies / blood. Magnetic Resonance Imaging. Male. Skin Neoplasms / drug therapy. Treatment Outcome


13. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D: Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology; 2000 Sep;32(3):466-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy.
  • We intended to compare these features with those of patients with portal cavernoma, and also to assess the incidence of recanalization of recent thrombosis on anticoagulation therapy.
  • All patients seen between 1983 and 1999 were enrolled into this retrospective study if recent portal or mesenteric venous thrombosis or portal cavernoma had been documented, and if cancer of the liver, pancreas, or bile duct, intrahepatic block including cirrhosis, and obstruction of the hepatic veins had been ruled out.
  • Patients with recent thrombosis (n = 33) or cavernoma (n = 108) did not differ with regard to age, sex ratio, or prevalence of prothrombotic states and of previous thrombotic events.
  • The features differentiating recent thrombosis and cavernoma are related to silent onset precluding early recognition and therapy in the latter.
  • Frequent association with prothrombotic states and frequent recanalization on anticoagulation support the recommendation of early anticoagulation therapy in all patients with recent portal vein thrombosis.
  • [MeSH-major] Anticoagulants / therapeutic use. Mesenteric Veins. Portal Vein. Venous Thrombosis / drug therapy
  • [MeSH-minor] Adult. Female. Hemangioma, Cavernous / drug therapy. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome


14. Hashimoto M, Sugawara M, Ishiyama K, Sato T, Yamamoto Y, Nanjo H: Reduction in the size of a hepatic haemangioma after chemotherapy. Liver Int; 2008 Aug;28(7):1043-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction in the size of a hepatic haemangioma after chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Hemangioma / drug therapy. Liver Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Etoposide / therapeutic use. Female. Humans. Hysterectomy. Magnetic Resonance Imaging. Neoplasms, Multiple Primary. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783545.001).
  • [ISSN] 1478-3231
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


15. Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, Kwiatkowski DJ: Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther; 2009 Jul;8(7):1799-807
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
  • We tested atorvastatin as a therapy for (a) ethylnitrosourea (ENU)-enhanced renal cystadenoma and (b) spontaneous liver hemangioma in 129Sv/Jae Tsc2(+/-) mice.
  • All treatment groups were compared with mice of identical genotype and strain background that were fed control chow.
  • Pathologic analyses revealed a predominance of renal cystadenoma in ENU-treated and liver hemangioma in non-ENU-treated 129Sv/Jae Tsc2(+/-) mice.
  • In both cohorts, serum cholesterol levels and levels of phosphorylated S6 and GTP-RhoA in healthy tissue were significantly (>50%) reduced in atorvastatin-treated mice as compared with controls.
  • Following atorvastatin treatment, no significant reduction in tumor size, morphology, or phosphorylated S6 levels was observed for either ENU-associated renal cystadenoma or spontaneous liver hemangioma as compared with the untreated groups.
  • In conclusion, although the marked reduction in cholesterol levels indicates that atorvastatin was effective as an 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, it did not inhibit the growth of tumors that develop in these Tsc2(+/-) models, suggesting that it is unlikely to have benefit as a single-agent therapy for TSC-associated tumors.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 May 4;105(3):357-68 [11348592.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):579-94 [16375664.001]
  • [Cites] Hum Mol Genet. 2002 Mar 1;11(5):525-34 [11875047.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10678-82 [11788600.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30958-67 [12045200.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):648-57 [12172553.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):593-613 [12616706.001]
  • [Cites] Curr Biol. 2003 Aug 5;13(15):1259-68 [12906785.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32493-6 [12842888.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):32-8 [14729330.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3436-43 [15150095.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4188-94 [14976045.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23114-22 [15039427.001]
  • [Cites] Cell Signal. 2004 Oct;16(10):1105-12 [15240005.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(18):7965-75 [15340059.001]
  • [Cites] N Engl J Med. 1988 Jul 7;319(1):24-33 [3288867.001]
  • [Cites] Nature. 1990 Feb 1;343(6257):425-30 [1967820.001]
  • [Cites] J Biol Chem. 1992 Oct 5;267(28):20033-8 [1400319.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Annu Rev Biochem. 1996;65:241-69 [8811180.001]
  • [Cites] Tohoku J Exp Med. 1996 Oct;180(2):131-8 [9111762.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • [Cites] Breast Cancer Res Treat. 1998 Jul;50(1):83-93 [9802623.001]
  • [Cites] J Cell Sci. 1998 Dec 18;111 ( Pt 24):3633-43 [9819354.001]
  • [Cites] J Clin Invest. 1999 Sep;104(6):687-95 [10491404.001]
  • [Cites] Arthritis Rheum. 2004 Dec;50(12):4051-9 [15593180.001]
  • [Cites] J Cell Biol. 2004 Dec 20;167(6):1171-82 [15611338.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8648-55 [15623649.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):213-27 [15578690.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Mar 15;171(6):606-15 [15591471.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):702-13 [15854902.001]
  • [Cites] J Surg Res. 2005 Nov;129(1):52-6 [16087194.001]
  • [Cites] Endothelium. 2005 Sep-Dec;12(5-6):233-41 [16410222.001]
  • [Cites] Med Res Rev. 2006 Mar;26(2):160-80 [16329102.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7370-7 [16849589.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5480-7 [17875778.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9878-86 [17942919.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • [Cites] Urology. 2008 Jan;71(1):118-22 [18242378.001]
  • [Cites] Transplantation. 2008 Feb 27;85(4):636-9 [18347544.001]
  • [Cites] Am J Med. 2008 Apr;121(4):302-9 [18374689.001]
  • [Cites] Liver Transpl. 2008 May;14(5):633-8 [18324656.001]
  • [Cites] Transplant Proc. 2008 Apr;40(3):711-3 [18454994.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1028-33 [18463402.001]
  • [Cites] Am J Cardiol. 2008 Jun 1;101(11):1560-6 [18489933.001]
  • [Cites] J Am Coll Cardiol. 2008 May 27;51(21):2017-24 [18498954.001]
  • [Cites] Ann Pharmacother. 2008 Jul;42(7):1143-5 [18559956.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):308-17 [11832446.001]
  • (PMID = 19584242.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K08 HL074113; United States / NHLBI NIH HHS / HL / K08 HL074113-03; United States / NCI NIH HHS / CA / P01 CA120964; United States / NHLBI NIH HHS / HL / K08 HL074113-05; United States / NHLBI NIH HHS / HL / HL074113-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heptanoic Acids; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Pyrroles; 0 / Tumor Suppressor Proteins; 48A5M73Z4Q / Atorvastatin Calcium; 4JG2LF96VF / tuberous sclerosis complex 2 protein; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ NIHMS119618; NLM/ PMC2712945
  •  go-up   go-down


16. Sarialioglu F, Erbay A, Demir S: Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy. Pediatr Blood Cancer; 2010 Dec 15;55(7):1433-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy.
  • [MeSH-major] Drug Resistance, Neoplasm. Hemangioendothelioma / drug therapy. Interferon-alpha / administration & dosage. Liver Neoplasms / drug therapy. Methylprednisolone / administration & dosage. Propranolol / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Infant. Male

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981697.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 9Y8NXQ24VQ / Propranolol; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


17. Ocama P, Katwere M, Piloya T, Feld J, Opio KC, Kambugu A, Katabira E, Thomas D, Colebunders R, Ronald A: The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci; 2008 Mar;8(1):8-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
  • BACKGROUND: Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections.
  • OBJECTIVE: To describe the spectrum of liver diseases in HIV-infected patients attending an HIV clinic in Kampala, Uganda.
  • METHOD: Consecutive patients presenting with jaundice, right upper quadrant pain with fever or malaise, ascites and/or tender hepatomegaly were recruited and underwent investigations to evaluate the cause of their liver disease.
  • Although 14 (61%) patients with drug-induced liver disease presented with jaundice, all recovered with drug discontinuation.
  • Probable granulomatous hepatitis due to tuberculosis was diagnosed in 7 (9%) patients and all responded to anti-TB therapy.
  • Other diagnoses included alcoholic liver disease, AIDS cholangiopathy, hepatocellular carcinoma, schistosomiasis, haemangioma and hepatic adenoma.
  • Twelve (16%) patients died during follow-up of which 7 (9%) died because of liver disease.
  • CONCLUSION: Drug history, liver enzyme studies, ultrasound, and hepatitis B and C investigations identified the probable etiology in 60 (78%) of 77 patients with HIV infection presenting with symptoms and/or signs of liver disease.
  • [MeSH-major] Anti-HIV Agents / adverse effects. Antitubercular Agents / adverse effects. HIV Infections / complications. HIV Infections / drug therapy. Isoniazid / adverse effects. Liver Diseases / epidemiology. Nevirapine / adverse effects. Reverse Transcriptase Inhibitors / adverse effects
  • [MeSH-minor] Comorbidity. Drug-Induced Liver Injury. Female. Follow-Up Studies. Humans. Immunocompromised Host. Incidence. Liver Neoplasms / epidemiology. Male. Prevalence. Time Factors. Treatment Outcome. Tuberculosis / drug therapy. Tuberculosis / epidemiology. Uganda

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. NEVIRAPINE .
  • Hazardous Substances Data Bank. ISONIAZID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2000 Jan 5;283(1):74-80 [10632283.001]
  • [Cites] J Int Assoc Physicians AIDS Care (Chic). 2007 Jun;6(2):83-6 [17537997.001]
  • [Cites] Med Sci Monit. 2001 Jul-Aug;7(4):729-36 [11433202.001]
  • [Cites] East Afr Med J. 2002 Feb;79(2):68-72 [12380879.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S80-9 [14986279.001]
  • [Cites] Clin Infect Dis. 2004 Aug 15;39(4):488-96 [15356811.001]
  • [Cites] J Med Virol. 2005 Feb;75(2):209-12 [15602740.001]
  • [Cites] East Afr Med J. 2005 Apr;82(4):170-2 [16122083.001]
  • [Cites] Ann Hepatol. 2005 Jul-Sep;4(3):188-91 [16177658.001]
  • [Cites] J Antimicrob Chemother. 2005 Dec;56(6):1087-93 [16269552.001]
  • [Cites] Antivir Ther. 2005;10(8):953-65 [16430201.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5005-9 [17075119.001]
  • [Cites] World J Gastroenterol. 2006 Nov 14;12(42):6879-83 [17106941.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1553-8 [17134360.001]
  • [Cites] AIDS Rev. 2007 Jan-Mar;9(1):40-53 [17474312.001]
  • [Cites] East Afr Med J. 2000 Jan;77(1):13-5 [10944831.001]
  • (PMID = 19357726.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antitubercular Agents; 0 / Reverse Transcriptase Inhibitors; 99DK7FVK1H / Nevirapine; V83O1VOZ8L / Isoniazid
  • [Other-IDs] NLM/ PMC2408539
  •  go-up   go-down


18. Niemelä M, Mäenpää H, Salven P, Summanen P, Poussa K, Laatikainen L, Jääskeläinen J, Joensuu H: Interferon alpha-2a therapy in 18 hemangioblastomas. Clin Cancer Res; 2001 Mar;7(3):510-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon alpha-2a therapy in 18 hemangioblastomas.
  • Multiple but thus far asymptomatic HBs pose a therapeutic problem.
  • IFN-alpha-2a has antiangiogenic activity with an especially favorable effect on life-threatening hemangiomas of the liver in children.
  • This is the first study to assess the efficacy of IFN-alpha-2a in treatment of asymptomatic HBs of the CNS and retina.
  • Four patients (three with VHL) with a combined total of 15 HBs of the CNS, 3 HBs of the retina, and 14 renal and 2 pancreatic cysts were treated with s.c.
  • IFN-alpha-2a for 12 months at 3 x 10(6) IU, 3 times/week.
  • No de novo HBs were detected during the therapy, but one appeared 9 months after cessation of IFN-alpha-2a therapy.
  • HBs of the CNS did not shrink markedly during the therapy.
  • However, the therapy did not prevent visceral cysts from growing.
  • The systemic response was also monitored by measurement of serum levels of vascular endothelial growth factor and erythropoietin, which remained essentially unchanged during the treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Hemangioblastoma / drug therapy. Interferon-alpha / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Endothelial Growth Factors / blood. Erythropoietin / blood. Female. Humans. Lymphokines / blood. Male. Middle Aged. Recombinant Proteins. Time Factors. Treatment Outcome. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11297241.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endothelial Growth Factors; 0 / Interferon-alpha; 0 / Lymphokines; 0 / Recombinant Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 11096-26-7 / Erythropoietin; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


19. Granov AM, Tiutin LA, Tarazov PG, Granov DA: [Modern technologies of diagnosis and combined surgical treatment in liver tumors]. Vestn Ross Akad Med Nauk; 2003;(10):51-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern technologies of diagnosis and combined surgical treatment in liver tumors].
  • Modern technologies used at St. Petersburg Central Research Institute of Roentgenology and Radiotherapy of Russia's Ministry of Health in the diagnosis and treatment of malignant and benign liver cancers are surveyed in the paper.
  • Apart from routine examinations, like ultrasound scanning, computer tomography, MRT, angiography, the below new technologies were widely used: multi-stratum spiral computer tomography, special MRT techniques and positron-emission tomography.
  • The new methods enabled us to diagnose the tumor and its extension, to choose an optimal intervention technique, to make an objective assessment of the results and to correct the treatment strategy.
  • Preoperative embolization of the portal-vein branches in the damaged hepatic lobe and postoperative adjuvant local chemotherapy of the hepatic artery and portal vein belong to the new combined surgical treatment scheme.
  • The method of combined arterial-portal chemoembolization, used in unresectable malignant hepatic pathologies, extends the survival of patients by 3-5 times.
  • Ferromagnetic embolization presupposes the administration of ferromagnetic, through the arterial bed or direct puncture, into the tumor with a subsequent SHF-current treatment which brings about a selective tumor hyperthermia without heating the normal hepatic parenchyma.
  • Arterial embolization combined with local injection sclerotherapy in hemangiomas of the liver provides for a complete regeneration of benign tumors and can be regarded as a low-trauma alternative to liver resection.
  • The use of new methods of diagnosis and treatment expands the possibilities of surgical care for patients with hepatic neoplasms and essentially improves the treatment results.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14598512.001).
  • [ISSN] 0869-6047
  • [Journal-full-title] Vestnik Rossiiskoi akademii meditsinskikh nauk
  • [ISO-abbreviation] Vestn. Akad. Med. Nauk SSSR
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down






Advertisement